Skip to main content

Inhibitex Inc



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 2.6%. By the end of trading, Inhibitex Inc rose 99 cents (9.2%) to $11.77 on heavy volume. Throughout the day, 4.3 million shares of Inhibitex Inc exchanged hands as compared to its average daily volume of 1.7 million shares. The stock ranged in a price between $10.68-$12.08 after having opened the day at $10.80 as compared to the previous trading day's close of $10.78. Other companies within the Drugs industry that increased today were:

Transcept Pharmaceuticals Inc



), up 11%,

Cormedix Inc



), up 9.6%,

Bionovo Inc



), up 9.2%, and

Scroll to Continue

TheStreet Recommends

MediciNova Inc



), up 7%.

Inhibitex, Inc., a biopharmaceutical company, focuses on the development of differentiated anti-infective products to prevent or treat serious infections. It primarily focuses to treat shingles caused by the varicella zoster virus and chronic infections caused by hepatitis C virus (HCV). Inhibitex Inc has a market cap of $830.7 million and is part of the

health care

sector. Shares are up 314.6% year to date as of the close of trading on Tuesday.

TheStreet Ratings rates Inhibitex as a


. The area that we feel has been the company's primary weakness has been its deteriorating net income.

On the negative front,

Rosetta Genomics



), down 43.3%,

Rosetta Genomics



), down 43.3%,

Accelr8 Technology Corporation



), down 16.4%, and

Bacterin International Holdings Inc



), down 14.7%, were all losers within the drugs industry with

Eli Lilly and Company



) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech